Litcius/Paper detail

Psoralen-Loaded Polymeric Lipid Nanoparticles Combined with Paclitaxel for The Treatment of Triple-Negative Breast Cancer

Fengjie Liu, Lihong Li, Meng Lan, Tengteng Zou, Zhaodi Kong, Tiange Cai, Xiaoyu Wu, Yu Cai

2021Nanomedicine23 citationsDOI

Abstract

Background: Chemotherapeutic drugs are associated with toxic effects. Metastasis is the leading cause of death in breast cancer patients. Aim: To evaluate the antitumor effect of paclitaxel (PTX) combined with psoralen-loaded polymeric lipid nanoparticles (PSO-PLNs) in triple-negative breast cancer. Methods: After treatment of samples, cell viability, apoptosis, migration, invasion, expression of proteins in the IRAK1/NF-κB/FAK signal pathway, biodistribution and pathological characteristics were detected. Results: Compared with the control group, the PTX + PSO-PLNs group showed increased apoptosis and reduced migration, invasion and expression of phosphorylated IRAK1 and NF-κB, with significant inhibition of tumor growth and lung metastases and no obvious toxicity. Conclusion: Combined administration of PTX and PSO-PLNs exerted a synergistic effect and significantly inhibited the growth and metastasis of triple-negative breast cancer.

Topics & Concepts

Triple-negative breast cancerPaclitaxelBreast cancerPsoralenApoptosisMetastasisCancer researchMedicineCancerChemotherapyMetastatic breast cancerToxicityChemistryPharmacologyInternal medicineBiochemistryDNACancer, Lipids, and MetabolismCurcumin's Biomedical ApplicationsSynthesis and biological activity
Psoralen-Loaded Polymeric Lipid Nanoparticles Combined with Paclitaxel for The Treatment of Triple-Negative Breast Cancer | Litcius